LES Licensing Executives Society
USA & CanadaLESI OrganizationTrustee Login

About Us
Membership
Calendar of Events
Meetings
Education
CLP
Local Chapters
Industry Sectors
Professional Interest Committees
Publications
Press Room
Licensing Resouces
Search/Sitemap
Member-Login


search
Calendar of Events

Meetings

LES 2007 Spring Meeting

Licensing In the Era of Intellectual Property Revolution

May 16-18, 2007
Grand Hyatt Atlanta in Buckhead
Atlanta, GA


Meeting Homepage

Speaker Presentations

Speaker Bios


Meeting Committee
Welcome from the Meeting Chair

Meeting Program:
Schedule at a Glance
Workshops at a Glance
Add-on Seminars
Plenary Sessions
Workshops
PDS Workshops
Licensing Foundation Sessions
CLE
Committee Meetings

Additional Events:
Networking Events
Tech Fair
Accompanying Persons

Sponsors:
Meeting Sponsors
Sponsor Opportunities

Miscellaneous Info:
Hotel
Weather and Dress
Discover Atlanta

Plenary Session

THURSDAY, MAY 17

8:15 a.m. — 10:15 a.m.
Welcome and Opening Remarks
Allen Baum, President, LES
Brian Oliver, LES 2007 Spring Meeting Chair


8:30 a.m. — 9:15 a.m.

Licensing Specialty Pharma:
The Views of an Industry Leader

Keynote Speaker: Matthew Emmens, Chief Executive Officer,
Shire Pharmaceuticals

Shire Pharmceuticals supports its growth strategy by acquiring or in-licensing additional R&D projects and marketed products. By merging with seven companies over a ten year period, Shire has been built faster than many other companies in the industry.

Hear the challenges and victories in in-licensing practices by a leader in the Health Care industry.

Matthew Emmens joined Shire Pharmaceuticals Group plc as Chief Executive and member of the board in March 2003. Mr. Emmens began his career in international pharmaceuticals in 1974 when he joined Merck & Co. He held a wide range of sales, marketing and training positions with Merck & Co before moving to help establish Astra Merck, the joint venture with Astra Pharmaceuticals. He later became its President and Chief Executive. Astra Merck Inc. became an independent, top 20 U.S. pharmaceutical company with annual sales in excess of $4 billion and 4000 employees. In 1999 Matthew joined Merck KGaA and established EMD Pharmaceuticals, the company's U.S. prescription pharmaceutical business.

9:15 a.m. — 10:15 a.m.
Beyond the License Agreement:
Revolutionary Intellectual Property Packaging

There are now more alternatives than ever before to generate a return on IP. From patent auctions to royalty securitizations to patent pooling to contingent fee litigation to patent-based stock market indexes to patent accumulation for invention investment... the list seems to be limited only by the creativity of the people involved in the IP marketplace. Who is actually doing the deals? Are these revolutionary deal structures more hype than reality? What do these revolutionary structures mean for the licensing executive? A panel of experts representing many of these business models will explore how these systems provide efficiency and economy to the IP market place.

Moderator
Michael Martin
, President, TechTransfer Associates, Inc.

Michael J. Martin is the President of TechTransfer Associates, a consulting practice that defines and develops value for intellectual property in universities, governments, and businesses. He has over 30 years of business and product development experience. Mike has held positions at DuPont, PPG Industries, Ciba-Geigy, Michigan State University and Virginia Tech. He has been appointed as a Trustee of the Licensing Executive Society (LES), responsible for Tech Transfer Seminars; is the past chair of the E-104 Section of the LES 2002-2003; and was the chair of LES E-04/01 "Polymers Chemicals and Energy" 2001 - 2002. He has given presentations at a number of LES annual and seasonal meetings. Mike was granted a Bachelor in Chemical Engineering from the University of Detroit and a Masters in Business from the U. of Delaware.

Panelists:
John B. Hall
, Managing Director Commercial Finance,
General Electric

John B. Hall Senior Vice President of GE Commercial Finance, is responsible for leading the Intellectual Property Finance practice of General Electric. In that capacity he has negotiated numerous highly structured financings involving a variety of intangible asset classes, including a previous LES "Deal of Distinction" award winning transaction for Motorola. Since joining GE in 2000, Mr. Hall has been utilized by the firm in a variety of roles across several of it's financial divisions.

Previously, Mr. Hall spent his extensive career in a number of commercial and investment banking businesses structuring leveraged financings and complex investment grade products.

Michael Lasinski, Managing Director, Ocean Tomo

Michael Lasinski is a Managing Director at Ocean Tomo and is in charge of the company's valuation practice area. Mr. Lasinski serves clients in the area of strategy, valuation and tax structure analysis. In the valuation area, he has valued intellectual property and businesses in the context of licensing, sale, purchase (including purchase price allocation), corporate spin-outs, joint ventures, litigation (reasonable royalty and economic damage analyses) and tax-related transactions. Mr. Lasinski has completed more than 200 valuations during his professional career. He has spoken on the topics of IP valuation, IP licensing and IP tax strategies throughout the U.S. as well as internationally.

William Marino, Partner and General Counsel, Altitude Capital

William Marino has extensive patent litigation experience and successfully litigated patents, trademarks and other intellectual property cases in U.S. District Courts. Prior to joining Altitude, he was a senior attorney at Robins, Kaplan, Miller and Ciresi and Mintz Levin Cohn Ferris Glovsky and Popeo. Mr. Marino had lead roles in litigating cases involving a range of technologies including computer hardware, microprocessors, sub-sea oil drilling equipment, medical devices and pharmaceuticals. Mr. Marino has also negotiated many patent licenses and other agreements involving intellectual property. Mr. Marino is a member of the bars of Massachusetts and the District of Columbia, and is admitted to practice before the U.S. Court of Appeals for the Federal Circuit, several U.S. District courts, and the U.S. Patent and Trademark Office.

Raymond P. Niro, Jr. , Partner, Niro Scavone, Haller & Niro

Raymond P. Niro, Jr.joined Niro, Scavone, Haller & Niro in 1991 and has participated in the trial of numerous high-stakes intellectual property disputes representing both individual inventors and large corporations. In December 2001, Mr. Niro won a $2.1 million jury verdict in a patent infringement case in Chicago as lead trial counsel. This verdict represented a royalty rate of 70% of defendant's sales. He has been deeply involved in many of the firm's major trials. In December 2003, Mr. Niro was retained by the Billy Goat Tavern to protect its famous slogan trademark against similarly-named Florida franchise that was expanding into the Chicago area. The verdict permanently enjoined defendants from opening any locations within a 125 miles of Chicago. Other highprofile case involvement includes Black & Decker SnakeLight and the yellow & black DeWalt power tools. Mr. Niro has also argued before District Courts throughout the country, as well as the ourt of Appeals for the Federal Circuit in Washington, DC.

12:00 P.M. — 1:45 P.M. LUNCHEON

LICENSING FOUNDATION GRADUATE STUDENT BUSINESS PLAN COMPETITION AWARDS PRESENTATION

Maximizing Consumer Brand Value
Speaker: G. Spencer Lueders, Jr., Esq., Competition and Patent Counsel, NASCAR

From beverage cozies to the latest technology for sound insulation and automotive safety, NASCAR's licensing agreements apply to a full spectrum of business and consumer-focused products.

G. Spencer Leuders, Jr., NASCAR Competition and Patent Counsel, will discuss the importance of licensing agreements to the NASCAR business model, and NASCAR's unique approach to product and technology licensing among their teams. Leuders will address how licensing products and innovative technology have played a key role in building and maintaining the NASCAR brand.

G. Spencer Leuders, Jr., Esq., attended the University of South Carolina (B.S. Mechanical Engineering) and School of Law, and is a registered Patent Attorney with the U.S. Patent and Trademark Office. Formerly in the Charlotte office of Atlanta-based law firm Alston & Bird LLP, Mr. Leuders is now Competition and Patent Counsel at NASCAR.

FRIDAY, MAY 18

8:00 a.m. — 10:15 a.m.

8:30 a.m. — 9:00 a.m.
A New Model in Research University Economic Development
G. Wayne Clough, Ph.D., President, Georgia Institute of Technology

G. Wayne Clough addresses the issues of innovation and competitiveness confronting Atlanta, the Southeast, and the U.S. As evidenced by Georgia Tech's growing investment in research and as one of the top ten public universities, Georgia Tech's commercialization throughout the region includes the forming of numerous start-up companies resulting from sponsored research.

In September, 1994, Dr. G. Wayne Clough became the tenth President of the Georgia Institute of Technology and the first alumnus to serve as president. Dr. Clough was a member of the faculty at Duke University, Stanford University, Virginia Tech, and the University of Washington. He served as Head of the Department of Civil Engineering and Dean of the College of Engineering at Virginia Tech, and as Provost and Vice President for Academic Affairs at the University of Washington. Dr. Clough received his B.S. and M.S. in Civil Engineering from Georgia Tech in 1964 and 1965, and a Ph.D. in 1969 in Civil Engineering from the University of California, Berkeley.

9:00 a.m. — 9:30 a.m.
Moving Target: Licensing and Uncertainty
Hank Barry, Director, Business Development, Howard Rice, Nemerovski, Canady, Falk & Rabkin

Mr. Barry will discuss how instant worldwide authorship, the integration of developing economies and worldwide IP law reform will affect rights and transactions in intellectual property in the next 10 years.

Hank Barry is a director at Howard Rice and is a member of the firm's Business Development and the Intellectual Property Counseling & Transactions group. Mr. Barry represents high growth technology companies at all stages of development, with a particular focus on intellectual property, commercial strategy and venture capital.

Prior to joining Howard Rice, Mr. Barry was a partner at Hummer Winblad Venture Partners and, on behalf of Hummer Winblad, served as CEO and a board member for Napster, Inc. from 2000 to 2002. Before joining Hummer Winblad, Mr. Barry was a partner at Wilson Sonsini Goodrich & Rosati, where he was the principal legal counsel to several pioneering Internet and digital media companies, including BizRate, Employease, Global Village Communications, Looksmart, Liquid Audio, NetDynamics and Upshot. He also represented several notable entertainment and consumer electronics companies, including A&M Records, Disney Online and Apple Computer.

9:30 a.m. — 10:15 a.m.
LES Specialty Pharma Summit: Financing, Finding Deals and IP Protection for Recycled Products
The specialty pharmaceutical business is attracting a lot of attention from investors. However, the challenges of identifying new product opportunities and exclusivity are extreme.

Come listen to and talk with the experts about strategies for identifying new product, partnerships that work, financing specialty pharma from initial investment through acquisition or IPO, and intellectual property/exclusivity strategies.

Panelists: David Pierson, Intersouth Partners

David Pierson brings 12 years of pharmaceutical industry experience to Intersouth Partners, where he works with the life science investment team. He joined Intersouth in early 2005 from New Jersey-based NPS Pharmaceuticals, where he built and launched the company's first specialty field sales organization. Prior to NPS, he was director of global marketing for Pharmacia Corporation's oncology franchise, managing the company's portfolio of branded oncology drugs in Europe and Latin America. He began his pharmaceutical career at Johnson & Johnson, advancing through a variety of sales and marketing management roles from managing sales territories to evaluating in-licensing and acquisition opportunities to launching marketing plans for new drugs in the U.S.

Daniel White, Vice President, Corporate Development, Alimera Sciences

Instrumental in the creation of Alimera Sciences, Daniel White served both as the CFO and VP of Corporate Development from the inception of the company. He shepherded the company through a $1.7 million angel round, a series A fund raising of million and a series B fund raising of $32 million which formed the initial capitalization of the company. Daniel was also responsible for the licenses for Soothe® and Alimera's phase III diabetic macular edema program. As VP of Corporate Development, Daniel currently oversees licensing and business development, intellectual property and contracts, and international development. Prior to Alimera, Daniel was Head of Business Development and Licensing for CIBA Vision, where he evaluated, negotiated and managed new business opportunities and transactions.

Michael Yeomans, Senior Vice President Global Business Development & Licensing, Bayer Healthcare Pharmaceuticals

Dr. Michael A. Yeomans was recently appointed Senior Vice President, Global Business Development and Licensing, Bayer Healthcare Pharmaceuticals.  He has more than thirty years experience in the pharmaceutical industry, including more than fifteen years in licensing and business development roles, most recently with the specialty pharmaceutical company Biovail Corporation, and prior to that with Aventis and Hoechst Group companies. He has been responsible for identifying, negotiating and closing numerous deals, including product licenses, patent licenses, strategic alliances, joint ventures and acquisitions.

Dr. Yeomans holds a Ph.D. in chemistry from the University of London and is an active member of the Royal Society of Chemistry and the Licensing Executives Society.

Joseph Zakrzewski, Chief Executive Officer, Xcellerex, Inc.

Joseph Zakrzewski joined Reliant in 2005 bringing significant operational expertise and over 17 years of experience in the pharmaceutical industry while serving as Vice President of Corporate Business at Eli Lilly and Company. There he was responsible for all business development transactions globally on behalf of Lilly. Mr. Zakrzewski held positions of increasing responsibility in business development since 1995. Previously, he worked in a variety of capacities at Lilly including research, development, manufacturing and finance. Mr. Zakrzewski is a member of the American Institute of Chemical Engineering and the Licensing Executives Society (LES). He currently serves as the Vice President of Industrial Sectors on the LES Board of Trustees.



site designed and programmed by Americaneagle.com, Inc.  
LES Home | About Us | Membership | Calendar of Events | Meetings | Education | Press Room | Publications
Local Chapters | Search/Sitemap | Member-Login | Foundation | Industry Sectors | Professional Interest Committees | LESI | Trustee Login | Contact Us